Delineation of HER2 Gene Status in Breast Carcinoma by Silver in Situ Hybridization is Reproducible among Laboratories and Pathologists

Carbone, Antonino; Botti, Gerardo; Gloghini, Annunziata; Simone, G.; Truini, Mauro; Curcio, Maria Pia; Gasparini, Patrizia; Mangia, Anita; Perin, Tiziana; Salvi, Sandra; Testi, Maria Adele; Verderio, Paolo

doi:10.2353/jmoldx.2008.080052

Cited by 41 publications

(28 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These results are consistent with previous studies reporting on concordance rates for HER2 silver enhanced in situ hybridization vs. fluorescence in situ hybridization of 96% (k ¼ 0.75, 95% CI) and 99%. 13,27 Additionally, we assessed the EGFR gene status with a semiquantitative polymerase chain reactionbased assay and compared the results with silver enhanced in situ hybridization. Semiquantitative polymerase chain reaction-based assay results concurred excellent with silver enhanced in situ hybridization findings (Po0.001) and showed high association with EGFR silver enhanced in situ hybridization.…”

Section: Discussionmentioning

confidence: 99%

Comparison of automated silver enhanced in situ hybridization and fluorescence in situ hybridization for evaluation of epidermal growth factor receptor status in human glioblastomas

et al. 2009

View full text Add to dashboard Cite

The epidermal growth factor receptor (EGFR) is amplified in approximately 40% of glioblastomas making it a compelling molecular target for therapy. Before starting a therapy targeting the EGFR pathway, accurate determining of EGFR status is a prerequisite. We evaluated the reliability of the novel automated silver enhanced in situ hybridization for the detection of EGFR gene amplification in human glioblastomas. EGFRamplification status was assessed in 93 cases of glioblastoma by silver enhanced in situ hybridization and compared with results of fluorescence in situ hybridization and immunohistochemistry. In a second cohort, silver enhanced in situ hybridization status was correlated with EGFR gene expression data. The EGFR gene was amplified in 25/90 tumours (28%) by silver enhanced in situ hybridization, and in 28/93 tumours (30%) by fluorescence in situ hybridization. The concordance rate for silver enhanced in situ hybridization and fluorescence in situ hybridization was 98%. Two glioblastomas were scored as being amplified by fluorescence in situ hybridization but not by silver enhanced in situ hybridization. Polymerase chain reaction-based EGFRamplification data were highly correlated with EGFR silver enhanced in situ hybridization. Altogether, 81 of 91 cases (89%) showed positivity for EGFR expression by immunohistochemistry. Although EGFR protein over expression was associated with gene amplification (r ¼ 0.40, Po0.001), there were 29 of 91 cases that showed a high EGFR protein level and no EGFR amplification by fluorescence in situ hybridization. The high concordance rate of silver enhanced in situ hybridization and fluorescence in situ hybridization for the detection of EGFR amplification in paraffin-embedded glioblastomas samples demonstrates that silver enhanced in situ hybridization is a valid and attractive alternative to fluorescence in situ hybridization. Silver enhanced in situ hybridization combines the advantages of bright field microscopy with fully automated analysis in a costeffective way thereby emphasizing its use for routine application in surgical pathology.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of automated silver enhanced in situ hybridization and fluorescence in situ hybridization for evaluation of epidermal growth factor receptor status in human glioblastomas

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Bu yöntem kantitatif bir yöntem olup değerlendiriciler arasındaki uyum yüksektir. Ayrıca SİSH ASCO/CAP kılavuzunun önerdiği floresan in situ hibridizasyon (FISH) ile %95 uyumlu olma kriterine uygundur (17).…”

Section: Introductionunclassified

Comparison of immunohistochemistry and fluorescence in situ hybridization for the analysis of her2/neu and topoisomerase ii-alpha status in human breast cancer

Pala¹,

Zekioğlu²,

Özdemir³

et al. 2010

TJPATH

View full text Add to dashboard Cite

Objective: The aim of the study is to evaluate HeR-2 gene amplification ratio in c-erbB-2 score 2 breast carcinoma cases which have been controversial for targeted terapy and determinate its correlation with pathologic prognostic factors. Material and Method:We analyzed 80 infiltrating breast carcinomas, which were immunohistochemically score 2 with silver in situ hybridization (SISH) assay to determine Her-2 gene amplification. Afterwards cases have been grouped as amplification positive (AP) and amplification negative (AN). These groups have been compared with each other to reveal their relationship with pathologic prognostic factors.Results: 30% of the cases showed HeR-2 gene amplification with SISH. Median age of patients in AP group was 50.3 (±11.4). Median age of AN group was 56.7 (±13.0). We found that tumors in AP group had much higher mitotic rate (p= 0.044). Mean metastatic lenf node number in AP group was 10, while it was only 1 in AN group. Lenfovascular invasion was the other striking parameter which showed statisticaly significant correlation with HeR-2 amplification. We didn't find any statisticaly significant correlation between HeR-2 amplification and tumor size, histologic grade, nuclear grade, diameter of the largest metastatic lenf node, steroid receptor expression and tumor necrosis. Conclusion:Tumors that show HeR-2 gene amplification have much higher mitotic rate, increased metastatic lenf node number and increased lenfovascular invasion rate. Unignorable part of controversial immunohistochemically c-erbB-2 score 2 cases show HeR-2 gene amplification and we need to confirm these cases with genetic tests. SISH is a cheap, easy and cantitative alternative.

show abstract

“…Until now, some studies have been performed to compare FISH and SISH methods with a correlation ratio of 89-98% (Dietel et al, 2007;Carbone et al, 2008;Papouchado et al, 2010;Ying et al, 2010;Park et al, 2011;Lee et al, 2012;Tvrdík et al, 2012). A correlation ratio of 92.3% was found in this study between FISH and SISH.…”

Section: Discussionmentioning

confidence: 50%

“…As a result, HER2 amplification in neoadjuvant therapy is directly related to the response to trastuzumab therapy. Baseline HER2/neu status identification with protein and/or genomic status is performed with immunohistochemistry and in situ hybridization (ISH), respectively (Dietel et al, 2007;Carbone et al, 2008;Francis et al, 2009;Bilous et al, 2012 to the fluorescence in situ hybridization (FISH) method, which is a generally accepted and commonly used in situ hybridization technique, and to compare the results of each method. HER2 and CEP17 status can be evaluated simultaneously with the newly developed "Dual-Color Probe".…”

Section: Introductionmentioning

confidence: 99%

Determination of HER2 Gene Amplification in Breast Cancer using Dual-color Silver Enhanced in situ Hybridization (dc-SISH) and Comparison with Fluorescence ISH (FISH)

Ünal

Karaveli²,

Peştereli³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: The two basic methods that are currently accepted to identify the HER2 status are immunohistochemistry and flyorescence in situ hybridization (FISH) . The aim of this study was to perform the dual-color silver in situ hybridization (dc-SISH) technique as an alternative to FISH. Materials and Methods: A total of 40 invasive breast carcinoma cases were assessed for HER2 gene amplification by FISH and dualcolor SISH. Results: Significant correlation was found in the HER2 expression results obtained with the two approaches (p=0.001, p<0.05). The concordance rate was 92.3%. Conclusions: Foutine practical use of the dc-SISH method, which is much easier to apply, score, and evaluate, has many advantages. HER2 and CEN17 status can be evaluated simultaneously with the newly developed "Dual-Color Probe". All these specifications and the reliable results obtained support the widespread use of SISH technique in clinical practice.

show abstract

Delineation of HER2 Gene Status in Breast Carcinoma by Silver in Situ Hybridization is Reproducible among Laboratories and Pathologists

Cited by 41 publications

References 37 publications

Comparison of automated silver enhanced in situ hybridization and fluorescence in situ hybridization for evaluation of epidermal growth factor receptor status in human glioblastomas

Comparison of automated silver enhanced in situ hybridization and fluorescence in situ hybridization for evaluation of epidermal growth factor receptor status in human glioblastomas

Comparison of immunohistochemistry and fluorescence in situ hybridization for the analysis of her2/neu and topoisomerase ii-alpha status in human breast cancer

Determination of HER2 Gene Amplification in Breast Cancer using Dual-color Silver Enhanced in situ Hybridization (dc-SISH) and Comparison with Fluorescence ISH (FISH)

Contact Info

Product

Resources

About